劳拉西泮对广泛性焦虑症患者的临床效果及QOL评分的影响(1)
【摘要】 目的：探讨劳拉西泮对广泛性焦虑症患者的临床效果及QOL评分的影响。方法：选取2018年1月-2019年4月本院收治的广泛性焦虑症患者96例，根据临床治疗药物的不同将其分为研究组和对照组，每组48例。对照组采用草酸艾司西酞普兰治疗，研究组采用劳拉西泮治疗。比较两组患者治疗效果、不同时间段焦虑评分、QOL评分、用药依从性及不良反应发生情况。结果：研究组治疗总有效率为95.8%，高于对照组的79.2%，差异有统计学意义(P<0.05)。入院时，两组SAS评分、HAMA评分比较，差异均无统计学意义(P>0.05);治疗1、2、3周，研究组SAS评分、HAMA评分均低于对照组，差异均有统计学意义(P<0.05)。治疗前，两组生理功能、生理职能、躯体疼痛、总体健康、活力、社会功能、情感职能及精神健康比较，差异均无统计学意义(P>0.05);治疗后，研究组上述各维度评分均高于对照组，差异均有统计学意义(P<0.05)。研究组依从性为93.8%，高于对照组的75.0%，差异有统计学意义(P<0.05)。研究组不良反应发生率为10.4%，少于对照组的39.6%，差异有统计学意义(P<0.05)。结论：广泛性焦虑症的治疗中，劳拉西泮的治疗效果显著，值得应用。
【关键词】 劳拉西泮 草酸艾司西酞普蘭 广泛性焦虑症 QOL评分 不良反应
[Abstract] Objective： To investigate the effect of Lorazepam on the clinical effect and QOL score of patients with generalized anxiety disorder. Method： A total of 96 patients with generalized anxiety disorder admitted to our hospital from January 2018 to April 2019 were selected， they were divided into study group and control group according to the clinical treatment drugs， 48 cases in each group. The control group was treated with Escitalopram Oxalate， the study group was treated with Lorazepam. Treatment effect， anxiety score， QOL score， medication compliance and adverse reactions were compared between the two groups. Result： The total effective rate in the study group was 95.8%， higher than 79.2% in the control group， the difference was statistically significant (P<0.05). On admission， SAS score and HAMA score were compared between the two groups， the differences were not statistically significant (P>0.05). After 1， 2， 3 weeks of treatment， the SAS score and HAMA score of the study group were lower than those of the control group， the differences were statistically significant (P<0.05). Before the treatment， comparison of physiological function， physiological function， physical pain， overall health， vitality， social function， emotional function and mental health between the two groups， the differences were not statistically significant (P>0.05). After treatment， the scores of the above dimensions in the study group were higher than those in the control group， all the differences were statistically significant (P<0.05). Compliance in the study group was 93.8%， higher than 75.0% in the control group， the difference was statistically significant (P<0.05). The incidence of adverse reactions in the study group was 10.4%， less than the 39.6% of the control group， the difference was statistically significant (P<0.05). Conclusion： In the treatment of generalized anxiety disorder， Lorazepam has a significant therapeutic effect and is worthy of application., 百拇医药(洪二郎 常凤坤 李德生 王会娟 秦轶灵)
【关键词】 劳拉西泮 草酸艾司西酞普蘭 广泛性焦虑症 QOL评分 不良反应
[Abstract] Objective： To investigate the effect of Lorazepam on the clinical effect and QOL score of patients with generalized anxiety disorder. Method： A total of 96 patients with generalized anxiety disorder admitted to our hospital from January 2018 to April 2019 were selected， they were divided into study group and control group according to the clinical treatment drugs， 48 cases in each group. The control group was treated with Escitalopram Oxalate， the study group was treated with Lorazepam. Treatment effect， anxiety score， QOL score， medication compliance and adverse reactions were compared between the two groups. Result： The total effective rate in the study group was 95.8%， higher than 79.2% in the control group， the difference was statistically significant (P<0.05). On admission， SAS score and HAMA score were compared between the two groups， the differences were not statistically significant (P>0.05). After 1， 2， 3 weeks of treatment， the SAS score and HAMA score of the study group were lower than those of the control group， the differences were statistically significant (P<0.05). Before the treatment， comparison of physiological function， physiological function， physical pain， overall health， vitality， social function， emotional function and mental health between the two groups， the differences were not statistically significant (P>0.05). After treatment， the scores of the above dimensions in the study group were higher than those in the control group， all the differences were statistically significant (P<0.05). Compliance in the study group was 93.8%， higher than 75.0% in the control group， the difference was statistically significant (P<0.05). The incidence of adverse reactions in the study group was 10.4%， less than the 39.6% of the control group， the difference was statistically significant (P<0.05). Conclusion： In the treatment of generalized anxiety disorder， Lorazepam has a significant therapeutic effect and is worthy of application., 百拇医药(洪二郎 常凤坤 李德生 王会娟 秦轶灵)
参见：首页 > 医疗版 > 疾病专题 > 精神内科 > 焦虑症